Top

BMC Gastroenterology

Published in:

Open Access 01-12-2023 | Cholangiocarcinoma | Research

Sevoflurane inhibits cholangiocarcinoma via Wnt/β-catenin signaling pathway

Authors: Hui Cheng, Qinfang Li

Published in: BMC Gastroenterology | Issue 1/2023

Abstract

Background

Cholangiocarcinoma (CCA) is a refractory malignancy derived from bile duct epithelial cells. This study aimed to explore the role and molecular mechanisms of action of sevoflurane in CCA.

Methods

CCK-8 assay was used to assess the proliferation of cholangiocarcinoma cells, and flow cytometry was used to detect cholangiocarcinoma cell apoptosis. The effects of sevoflurane on TFK1 and QBC939 cell migration and invasion were investigated using a Transwell assay. Western blotting and RT-qPCR were used to assess the expression of apoptosis-related proteins and genes, and gene expression of the Wnt/β-catenin signaling pathway.

Results

Our study found that sevoflurane inhibited cholangiocarcinoma cell proliferation in a dose-dependent manner. In addition, sevoflurane induced cholangiocarcinoma cell apoptosis, inhibited cholangiocarcinoma cell migration and invasion, as well as the Wnt/β-catenin signaling pathway evidenced by decreased Wnt3a, β-catenin, c-Myc, and Cyclin D1 protein and mRNA expression, reduced p-GSK3β protein expression and p-GSK3β/GSK3β ratio. Further mechanistic studies revealed that Wnt/β-catenin pathway inducer SKL2001 reversed the inhibitory effect of sevoflurane on cholangiocarcinoma cells.

Conclusions

Sevoflurane induces apoptosis and inhibits the growth, migration, and invasion of cholangiocarcinoma cells by inhibiting the Wnt/β-catenin signaling pathway. This study not only revealed the role of sevoflurane in the development of CCA but also elucidated new therapeutic agents for CCA.

Available only for authorised users

Razumilava N, Gores GJ, Cholangiocarcinoma. The Lancet. 2014;383(9935):2168–79. https://doi.org/10.1016/s0140-6736(13)61903-0.CrossRef

Sarcognato S, Jong IEM, Fabris L, Cadamuro M, Guido M. Necroptosis in Cholangiocarcinoma Cells. 2020;9(4). https://doi.org/10.3390/cells9040982.

Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nat reviews Gastroenterol Hepatol. 2011;8(9):512–22. https://doi.org/10.1038/nrgastro.2011.131.CrossRef

Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013;145(6):1215–29. https://doi.org/10.1053/j.gastro.2013.10.013.CrossRefPubMed

Labib PL, Goodchild G, Pereira SP. Molecular Pathogenesis of Cholangiocarcinoma. BMC Cancer. 2019;19(1):185. https://doi.org/10.1186/s12885-019-5391-0.CrossRefPubMedPubMedCentral

Gorji L, Beal EW. Surgical Treatment of Distal Cholangiocarcinoma. Curr Oncol. 2022;29(9):6674–87. https://doi.org/10.3390/curroncol29090524.CrossRefPubMedPubMedCentral

Liang TY, Peng SY, Ma M, Li HY, Wang Z, Chen G. Protective effects of sevoflurane in cerebral ischemia reperfusion injury: a narrative review. Med Gas Res. 2021;11(4):152–54. https://doi.org/10.4103/2045-9912.318860.CrossRefPubMedPubMedCentral

De Hert S, Moerman A, Sevoflurane. F1000Research 2015;4(F1000 Faculty Rev):626 doi: https://doi.org/10.12688/f1000research.6288.1.

Hirai T, Konishi Y, Mizuno S, Rui Z, Sun Y, Nishiwaki K. Differential effects of sevoflurane on the growth and apoptosis of human cancer cell lines. J Anesth. 2020;34(1):47–57. https://doi.org/10.1007/s00540-019-02701-w.CrossRefPubMed

10.

Liu J, Yang L, Guo X, Jin G, Wang Q, Lv D, Liu J, Chen Q, Song Q, Li B. Sevoflurane suppresses proliferation by upregulating microRNA-203 in breast cancer cells. Mol Med Rep. 2018;18(1):455–60. https://doi.org/10.3892/mmr.2018.8949.CrossRefPubMed

11.

Deng X, Vipani M, Liang G, Gouda D, Wang B, Wei H. Sevoflurane modulates breast cancer cell survival via modulation of intracellular calcium homeostasis. BMC Anesthesiol. 2020;20(1):253. https://doi.org/10.1186/s12871-020-01139-y.CrossRefPubMedPubMedCentral

12.

He J, Zhao H, Liu X, Wang D, Wang Y, Ai Y, Yang J. Sevoflurane suppresses cell viability and invasion and promotes cell apoptosis in colon cancer by modulating exosomemediated circHMGCS1 via the miR34a5p/SGPP1 axis. Oncol Rep. 2020;44(6):2429–42. https://doi.org/10.3892/or.2020.7783.CrossRefPubMedPubMedCentral

13.

Wu T, Sun L, Wang C, Yu P, Cheng L, Chen Y. Sevoflurane suppresses the Migration, Invasion, and epithelial-mesenchymal transition of breast Cancer cells through the miR-139-5p/ARF6 Axis. J Surg Res. 2021;258:314–23. https://doi.org/10.1016/j.jss.2020.08.051.CrossRefPubMed

14.

Su G, Yan Z, Deng M. Sevoflurane inhibits Proliferation, Invasion, but enhances apoptosis of Lung Cancer cells by Wnt/beta-catenin signaling via regulating lncRNA PCAT6/miR-326 Axis. Open life sciences. 2020;15:159–72. https://doi.org/10.1515/biol-2020-0017.CrossRefPubMedPubMedCentral

15.

Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell. 2012;149(6):1192–205. https://doi.org/10.1016/j.cell.2012.05.012.CrossRefPubMed

16.

Nusse R, Clevers H. Wnt/beta-Catenin signaling, Disease, and emerging therapeutic modalities. Cell. 2017;169(6):985–99. https://doi.org/10.1016/j.cell.2017.05.016.CrossRefPubMed

17.

Yu F, Yu C, Li F, Zuo Y, Wang Y, Yao L, Wu C, Wang C, Ye L. Wnt/beta-catenin signaling in cancers and targeted therapies. Signal Transduct Target therapy. 2021;6(1):307. https://doi.org/10.1038/s41392-021-00701-5.CrossRef

18.

He S, Tang S. WNT/β-catenin signaling in the development of liver cancers. Biomed Pharmacother. 2020;132:110851. https://doi.org/10.1016/j.biopha.2020.110851.CrossRefPubMed

19.

Yang XZ, Cheng TT, He QJ, Lei ZY, Chi J, Tang Z, Liao QX, Zhang H, Zeng LS, Cui SZ. LINC01133 as ceRNA inhibits gastric cancer progression by sponging miR-106a-3p to regulate APC expression and the Wnt/beta-catenin pathway. Mol Cancer. 2018;17(1):126. https://doi.org/10.1186/s12943-018-0874-1.CrossRefPubMedPubMedCentral

20.

Zhang GF, Qiu L, Yang SL, Wu JC, Liu TJ. Wnt/beta-catenin signaling as an emerging potential key pharmacological target in cholangiocarcinoma. Biosci Rep. 2020;40(3). https://doi.org/10.1042/BSR20193353.

21.

Pangestu NS, Chueakwon P, Talabnin K, Khiaowichit J, Talabnin C. RNF43 overexpression attenuates the Wnt/beta-catenin signalling pathway to suppress tumour progression in cholangiocarcinoma. Oncol Lett. 2021;22(6):846. https://doi.org/10.3892/ol.2021.13107.CrossRefPubMedPubMedCentral

22.

Song F, Chen FY, Wu SY, Hu B, Liang XL, Yang HQ, Cheng JW, Wang PX, Guo W, Zhou J, Fan J, Chen Z, Yang XR. Mucin 1 promotes tumor progression through activating WNT/beta-catenin signaling pathway in intrahepatic cholangiocarcinoma. J Cancer. 2021;12(23):6937–47. https://doi.org/10.7150/jca.63235.CrossRefPubMedPubMedCentral

23.

Ma JF, Li CG, Sun MY, Shao GF, Li KZ. Isoflurane and sevoflurane affects Wnt/β-catenin signaling pathways in hippocampal formation of neonatal rats. Eur Rev Med Pharmacol Sci. 2017;21(8):1980–9.PubMed

24.

Liu S, Fang F, Song R, Gao X, Jiang M, Cang J. Sevoflurane affects neurogenesis through cell cycle arrest via inhibiting wnt/beta-catenin signaling pathway in mouse neural stem cells. Life Sci. 2018;209:34–42. https://doi.org/10.1016/j.lfs.2018.07.054.CrossRefPubMed

25.

Yong F, Wang H, Li C, Jia H. Sevoflurane represses the migration and invasion of gastric cancer cells by regulating forkhead box protein 3. J Int Med Res. 2021;49(4):3000605211005936. https://doi.org/10.1177/03000605211005936.CrossRefPubMed

26.

Marshall J. Transwell((R)) invasion assays. Methods Mol Biol. 2011;769:97–110. https://doi.org/10.1007/978-1-61779-207-6_8.CrossRefPubMed

27.

Suksen K, Janpipatkul K, Reabroi S, Anantachoke N, Reutrakul V, Chairoungdua A, Thongon N, Bhukhai K. Gambogic Acid inhibits Wnt/beta-catenin signaling and induces ER stress-mediated apoptosis in human cholangiocarcinoma. Asian Pac J cancer prevention: APJCP. 2021;22(6):1913–20. https://doi.org/10.31557/APJCP.2021.22.6.1913.CrossRef

28.

Zhang W, Sheng B, Chen S, Zhao H, Wu L, Sun Y, Cui J, Zhu X, Ma D. Sevoflurane enhances proliferation, metastatic potential of cervical Cancer cells via the histone deacetylase 6 Modulation in Vitro. Anesthesiology. 2020;132(6):1469–81. https://doi.org/10.1097/ALN.0000000000003129.CrossRefPubMed

29.

Zhao H, Xing F, Yuan J, Li Z, Zhang W. Sevoflurane inhibits migration and invasion of glioma cells via regulating miR-34a-5p/MMP-2 axis. Life Sci. 2020;256:117897. https://doi.org/10.1016/j.lfs.2020.117897.CrossRefPubMed

30.

Xue W, Dong B, Zhao Y, Wang Y, Yang C, Xie Y, Niu Z, Zhu C. Upregulation of TTYH3 promotes epithelial-to-mesenchymal transition through Wnt/β-catenin signaling and inhibits apoptosis in cholangiocarcinoma. Cell Oncol (Dordr). 2021;44(6):1351–61. https://doi.org/10.1007/s13402-021-00642-9.CrossRefPubMed

31.

Jiang Y, Liu Y, Sun Y, Liu Y, Feng L, Duan M, Liu Y, Xu L. Sevoflurane induces microRNA-18a to delay rat neurodevelopment via suppression of the RUNX1/Wnt/beta-catenin axis. Cell death discovery. 2022;8(1):404. https://doi.org/10.1038/s41420-022-01179-y.CrossRefPubMedPubMedCentral

32.

Wang F, Li C, Shao J, Ma J. Sevoflurane induces inflammation of microglia in hippocampus of neonatal rats by inhibiting Wnt/beta-Catenin/CaMKIV pathway. J Pharmacol Sci. 2021;146(2):105–15. https://doi.org/10.1016/j.jphs.2021.02.004.CrossRefPubMed

33.

Fan L, Wu Y, Wang J, He J, Han X. Sevoflurane inhibits the migration and invasion of colorectal cancer cells through regulating ERK/MMP-9 pathway by up-regulating miR-203. Eur J Pharmacol. 2019;850:43–52. https://doi.org/10.1016/j.ejphar.2019.01.025.CrossRefPubMed

Title: Sevoflurane inhibits cholangiocarcinoma via Wnt/β-catenin signaling pathway
Authors: Hui Cheng
Qinfang Li
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Cholangiocarcinoma
Cholangiocarcinoma
Published in: BMC Gastroenterology / Issue 1/2023
Electronic ISSN: 1471-230X
DOI: https://doi.org/10.1186/s12876-023-02911-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

Personalized colorectal cancer screening: study protocol of a mixed-methods study on the effectiveness of tailored intervals based on prior f-Hb concentration in a fit-based colorectal cancer screening program (PERFECT-FIT)

Long-term safety of brazikumab in the open-label period of a randomized phase 2a study of patients with Crohn’s disease

The comparison of an accessible C-shaped partial stapled hemorrhoidopexy (C-PSH) versus circular stapled hemorrhoidopexy (CSH) in patients with grade IV hemorrhoids: a retrospective cohort study

Laboratory risk factors for coexistent primary biliary cholangitis in patients with Sjögren’s syndrome: a retrospective study

Predicting the risk of early bleeding following endoscopic variceal ligation in cirrhotic patients with computed tomography

Identifying inflammatory bowel disease patients at risk of metabolic dysfunction-associated fatty liver disease: usefulness of non-invasive steatosis predictive scores

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials